Dopamine agonists for early Parkinson disease

American Family Physician

Volumn 80, Issue 1, 2009, Pages 28-30

  Hitzeman, Nathan ^a   Rafii, Flora ^a  

^a Sutter Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; APOMORPHINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PERGOLIDE MESILATE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE;

CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; EDEMA; GENETIC PREDISPOSITION; HALLUCINATION; HUMAN; META ANALYSIS; NAUSEA; PARKINSON DISEASE; QUALITY OF LIFE; RISK FACTOR; SHORT SURVEY; SOMNOLENCE; SYSTEMATIC REVIEW; TREMOR;

EID: 67650470372     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev. 2008;(2):CD006564.
2. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med. 2005;353(10):1021-1027.
3. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002;58(1):11-17.
4. LeWitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008;359(23):2468-2476.
5. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009;301(1):63-73.
6. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54(1):93-101.
7. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653-1661.
8. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23(15):2194-2201.
9. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-2170.